The portfolio maintains a cost advantage over competitors, priced within the lowest fee quintile among peers.
SPDR® S&P Pharmaceuticals ETF XPH
Morningstar’s Analysis XPH
Will XPH outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 48.0
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Intra-Cellular Therapies Inc | 5.79 | 11.3 Mil | Healthcare |
Merck & Co Inc | 4.95 | 9.7 Mil | Healthcare |
Catalent Inc | 4.83 | 9.4 Mil | Healthcare |
Eli Lilly and Co | 4.79 | 9.4 Mil | Healthcare |
Perrigo Co PLC | 4.77 | 9.3 Mil | Healthcare |
Organon & Co Ordinary Shares | 4.71 | 9.2 Mil | Healthcare |
Pfizer Inc | 4.61 | 9.0 Mil | Healthcare |
Axsome Therapeutics Inc | 4.55 | 8.9 Mil | Healthcare |
Jazz Pharmaceuticals PLC | 4.53 | 8.8 Mil | Healthcare |
Viatris Inc | 4.44 | 8.7 Mil | Healthcare |